nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLC22A6—Methazolamide—glaucoma	0.102	0.239	CbGbCtD
Dabrafenib—SLC22A6—Acetazolamide—glaucoma	0.0818	0.191	CbGbCtD
Dabrafenib—CYP3A4—Pilocarpine—glaucoma	0.0405	0.0946	CbGbCtD
Dabrafenib—ABCB1—Timolol—glaucoma	0.0388	0.0907	CbGbCtD
Dabrafenib—ABCB1—Clonidine—glaucoma	0.033	0.0771	CbGbCtD
Dabrafenib—CYP3A4—Brinzolamide—glaucoma	0.0317	0.0742	CbGbCtD
Dabrafenib—CYP3A4—Dorzolamide—glaucoma	0.0307	0.0717	CbGbCtD
Dabrafenib—CYP3A4—Methazolamide—glaucoma	0.0273	0.0639	CbGbCtD
Dabrafenib—CYP3A4—Acetazolamide—glaucoma	0.0218	0.0511	CbGbCtD
Dabrafenib—CYP3A4—Clonidine—glaucoma	0.0198	0.0462	CbGbCtD
Dabrafenib—Hypotension—Brimonidine—glaucoma	0.000456	0.0012	CcSEcCtD
Dabrafenib—Nausea—Levobunolol—glaucoma	0.000456	0.0012	CcSEcCtD
Dabrafenib—Infection—Brinzolamide—glaucoma	0.000455	0.0012	CcSEcCtD
Dabrafenib—Nervous system disorder—Travoprost—glaucoma	0.000455	0.0012	CcSEcCtD
Dabrafenib—Nasopharyngitis—Timolol—glaucoma	0.000455	0.0012	CcSEcCtD
Dabrafenib—Epistaxis—Betaxolol—glaucoma	0.000453	0.00119	CcSEcCtD
Dabrafenib—Skin disorder—Travoprost—glaucoma	0.000451	0.00118	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dorzolamide—glaucoma	0.000451	0.00118	CcSEcCtD
Dabrafenib—Abdominal pain—Apraclonidine—glaucoma	0.000449	0.00118	CcSEcCtD
Dabrafenib—Nervous system disorder—Brinzolamide—glaucoma	0.000449	0.00118	CcSEcCtD
Dabrafenib—Angiopathy—Clonidine—glaucoma	0.000449	0.00118	CcSEcCtD
Dabrafenib—Rash—Latanoprost—glaucoma	0.000448	0.00118	CcSEcCtD
Dabrafenib—Dermatitis—Latanoprost—glaucoma	0.000448	0.00118	CcSEcCtD
Dabrafenib—Mediastinal disorder—Clonidine—glaucoma	0.000446	0.00117	CcSEcCtD
Dabrafenib—Headache—Latanoprost—glaucoma	0.000446	0.00117	CcSEcCtD
Dabrafenib—Skin disorder—Brinzolamide—glaucoma	0.000445	0.00117	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Brimonidine—glaucoma	0.000445	0.00117	CcSEcCtD
Dabrafenib—Arrhythmia—Clonidine—glaucoma	0.000442	0.00116	CcSEcCtD
Dabrafenib—Decreased appetite—Acetazolamide—glaucoma	0.000442	0.00116	CcSEcCtD
Dabrafenib—Insomnia—Brimonidine—glaucoma	0.000441	0.00116	CcSEcCtD
Dabrafenib—Oedema—Pilocarpine—glaucoma	0.00044	0.00116	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000439	0.00115	CcSEcCtD
Dabrafenib—Fatigue—Acetazolamide—glaucoma	0.000438	0.00115	CcSEcCtD
Dabrafenib—Infection—Pilocarpine—glaucoma	0.000438	0.00115	CcSEcCtD
Dabrafenib—Alopecia—Clonidine—glaucoma	0.000438	0.00115	CcSEcCtD
Dabrafenib—Nausea—Methazolamide—glaucoma	0.000436	0.00115	CcSEcCtD
Dabrafenib—Hypotension—Dorzolamide—glaucoma	0.000436	0.00114	CcSEcCtD
Dabrafenib—Mental disorder—Clonidine—glaucoma	0.000434	0.00114	CcSEcCtD
Dabrafenib—Hypotension—Travoprost—glaucoma	0.000434	0.00114	CcSEcCtD
Dabrafenib—Thrombocytopenia—Pilocarpine—glaucoma	0.000431	0.00113	CcSEcCtD
Dabrafenib—Erythema—Clonidine—glaucoma	0.000431	0.00113	CcSEcCtD
Dabrafenib—Hypotension—Brinzolamide—glaucoma	0.000428	0.00112	CcSEcCtD
Dabrafenib—Hyperhidrosis—Pilocarpine—glaucoma	0.000426	0.00112	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000425	0.00112	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Travoprost—glaucoma	0.000423	0.00111	CcSEcCtD
Dabrafenib—Insomnia—Dorzolamide—glaucoma	0.000422	0.00111	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000421	0.00111	CcSEcCtD
Dabrafenib—Fatigue—Brimonidine—glaucoma	0.000421	0.00111	CcSEcCtD
Dabrafenib—Hypersensitivity—Apraclonidine—glaucoma	0.000419	0.0011	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000418	0.0011	CcSEcCtD
Dabrafenib—Insomnia—Brinzolamide—glaucoma	0.000415	0.00109	CcSEcCtD
Dabrafenib—Muscle spasms—Clonidine—glaucoma	0.000414	0.00109	CcSEcCtD
Dabrafenib—Hypotension—Pilocarpine—glaucoma	0.000412	0.00108	CcSEcCtD
Dabrafenib—Asthenia—Apraclonidine—glaucoma	0.000408	0.00107	CcSEcCtD
Dabrafenib—Vision blurred—Clonidine—glaucoma	0.000406	0.00107	CcSEcCtD
Dabrafenib—Decreased appetite—Dorzolamide—glaucoma	0.000405	0.00106	CcSEcCtD
Dabrafenib—Eye disorder—Betaxolol—glaucoma	0.000403	0.00106	CcSEcCtD
Dabrafenib—Pruritus—Apraclonidine—glaucoma	0.000402	0.00106	CcSEcCtD
Dabrafenib—Body temperature increased—Acetazolamide—glaucoma	0.000402	0.00106	CcSEcCtD
Dabrafenib—Fatigue—Dorzolamide—glaucoma	0.000402	0.00106	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.000401	0.00105	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Travoprost—glaucoma	0.000401	0.00105	CcSEcCtD
Dabrafenib—Fatigue—Travoprost—glaucoma	0.0004	0.00105	CcSEcCtD
Dabrafenib—Insomnia—Pilocarpine—glaucoma	0.000398	0.00105	CcSEcCtD
Dabrafenib—Decreased appetite—Brinzolamide—glaucoma	0.000398	0.00105	CcSEcCtD
Dabrafenib—Constipation—Travoprost—glaucoma	0.000397	0.00104	CcSEcCtD
Dabrafenib—Hyperglycaemia—Timolol—glaucoma	0.000397	0.00104	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000396	0.00104	CcSEcCtD
Dabrafenib—Asthenia—Bimatoprost—glaucoma	0.000396	0.00104	CcSEcCtD
Dabrafenib—Fatigue—Brinzolamide—glaucoma	0.000395	0.00104	CcSEcCtD
Dabrafenib—Angiopathy—Betaxolol—glaucoma	0.000391	0.00103	CcSEcCtD
Dabrafenib—Pruritus—Bimatoprost—glaucoma	0.00039	0.00102	CcSEcCtD
Dabrafenib—Immune system disorder—Betaxolol—glaucoma	0.000389	0.00102	CcSEcCtD
Dabrafenib—Diarrhoea—Apraclonidine—glaucoma	0.000389	0.00102	CcSEcCtD
Dabrafenib—Mediastinal disorder—Betaxolol—glaucoma	0.000388	0.00102	CcSEcCtD
Dabrafenib—Chills—Betaxolol—glaucoma	0.000387	0.00102	CcSEcCtD
Dabrafenib—Arrhythmia—Betaxolol—glaucoma	0.000385	0.00101	CcSEcCtD
Dabrafenib—Decreased appetite—Pilocarpine—glaucoma	0.000383	0.00101	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dorzolamide—glaucoma	0.000381	0.001	CcSEcCtD
Dabrafenib—Alopecia—Betaxolol—glaucoma	0.000381	0.001	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.00038	0.000999	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Travoprost—glaucoma	0.00038	0.000997	CcSEcCtD
Dabrafenib—Mental disorder—Betaxolol—glaucoma	0.000378	0.000992	CcSEcCtD
Dabrafenib—Constipation—Pilocarpine—glaucoma	0.000377	0.000989	CcSEcCtD
Dabrafenib—Cough—Clonidine—glaucoma	0.000376	0.000988	CcSEcCtD
Dabrafenib—Dizziness—Apraclonidine—glaucoma	0.000376	0.000987	CcSEcCtD
Dabrafenib—Malnutrition—Betaxolol—glaucoma	0.000375	0.000985	CcSEcCtD
Dabrafenib—Erythema—Betaxolol—glaucoma	0.000375	0.000985	CcSEcCtD
Dabrafenib—Epistaxis—Timolol—glaucoma	0.00037	0.000972	CcSEcCtD
Dabrafenib—Body temperature increased—Dorzolamide—glaucoma	0.000369	0.000968	CcSEcCtD
Dabrafenib—Abdominal pain—Dorzolamide—glaucoma	0.000369	0.000968	CcSEcCtD
Dabrafenib—Arthralgia—Clonidine—glaucoma	0.000367	0.000964	CcSEcCtD
Dabrafenib—Abdominal pain—Travoprost—glaucoma	0.000367	0.000964	CcSEcCtD
Dabrafenib—Asthenia—Acetazolamide—glaucoma	0.000365	0.000958	CcSEcCtD
Dabrafenib—Dizziness—Bimatoprost—glaucoma	0.000365	0.000957	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000364	0.000957	CcSEcCtD
Dabrafenib—Vomiting—Apraclonidine—glaucoma	0.000362	0.000949	CcSEcCtD
Dabrafenib—Muscle spasms—Betaxolol—glaucoma	0.000361	0.000947	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Pilocarpine—glaucoma	0.00036	0.000946	CcSEcCtD
Dabrafenib—Hypersensitivity—Brimonidine—glaucoma	0.00036	0.000944	CcSEcCtD
Dabrafenib—Dry mouth—Clonidine—glaucoma	0.000359	0.000942	CcSEcCtD
Dabrafenib—Dermatitis—Apraclonidine—glaucoma	0.000358	0.000941	CcSEcCtD
Dabrafenib—Headache—Apraclonidine—glaucoma	0.000356	0.000935	CcSEcCtD
Dabrafenib—Vision blurred—Betaxolol—glaucoma	0.000354	0.000929	CcSEcCtD
Dabrafenib—Oedema—Clonidine—glaucoma	0.000352	0.000924	CcSEcCtD
Dabrafenib—Asthenia—Brimonidine—glaucoma	0.00035	0.00092	CcSEcCtD
Dabrafenib—Infection—Clonidine—glaucoma	0.000349	0.000918	CcSEcCtD
Dabrafenib—Body temperature increased—Pilocarpine—glaucoma	0.000348	0.000914	CcSEcCtD
Dabrafenib—Abdominal pain—Pilocarpine—glaucoma	0.000348	0.000914	CcSEcCtD
Dabrafenib—Diarrhoea—Acetazolamide—glaucoma	0.000348	0.000914	CcSEcCtD
Dabrafenib—Rash—Bimatoprost—glaucoma	0.000348	0.000913	CcSEcCtD
Dabrafenib—Dermatitis—Bimatoprost—glaucoma	0.000347	0.000912	CcSEcCtD
Dabrafenib—Oedema peripheral—Timolol—glaucoma	0.000347	0.000911	CcSEcCtD
Dabrafenib—Anaemia—Betaxolol—glaucoma	0.000347	0.000911	CcSEcCtD
Dabrafenib—Connective tissue disorder—Timolol—glaucoma	0.000346	0.000909	CcSEcCtD
Dabrafenib—Pruritus—Brimonidine—glaucoma	0.000345	0.000907	CcSEcCtD
Dabrafenib—Headache—Bimatoprost—glaucoma	0.000345	0.000907	CcSEcCtD
Dabrafenib—Nervous system disorder—Clonidine—glaucoma	0.000345	0.000906	CcSEcCtD
Dabrafenib—Thrombocytopenia—Clonidine—glaucoma	0.000344	0.000904	CcSEcCtD
Dabrafenib—Hypersensitivity—Dorzolamide—glaucoma	0.000343	0.000902	CcSEcCtD
Dabrafenib—Hypersensitivity—Travoprost—glaucoma	0.000342	0.000898	CcSEcCtD
Dabrafenib—Skin disorder—Clonidine—glaucoma	0.000342	0.000897	CcSEcCtD
Dabrafenib—Hyperhidrosis—Clonidine—glaucoma	0.00034	0.000893	CcSEcCtD
Dabrafenib—Nausea—Apraclonidine—glaucoma	0.000338	0.000887	CcSEcCtD
Dabrafenib—Hypersensitivity—Brinzolamide—glaucoma	0.000338	0.000887	CcSEcCtD
Dabrafenib—Dizziness—Acetazolamide—glaucoma	0.000336	0.000883	CcSEcCtD
Dabrafenib—Asthenia—Dorzolamide—glaucoma	0.000334	0.000878	CcSEcCtD
Dabrafenib—Asthenia—Travoprost—glaucoma	0.000333	0.000875	CcSEcCtD
Dabrafenib—Pruritus—Dorzolamide—glaucoma	0.00033	0.000866	CcSEcCtD
Dabrafenib—Eye disorder—Timolol—glaucoma	0.000329	0.000864	CcSEcCtD
Dabrafenib—Asthenia—Brinzolamide—glaucoma	0.000329	0.000864	CcSEcCtD
Dabrafenib—Hypotension—Clonidine—glaucoma	0.000329	0.000863	CcSEcCtD
Dabrafenib—Pruritus—Travoprost—glaucoma	0.000328	0.000862	CcSEcCtD
Dabrafenib—Cough—Betaxolol—glaucoma	0.000327	0.00086	CcSEcCtD
Dabrafenib—Nausea—Bimatoprost—glaucoma	0.000327	0.00086	CcSEcCtD
Dabrafenib—Hypersensitivity—Pilocarpine—glaucoma	0.000325	0.000852	CcSEcCtD
Dabrafenib—Pruritus—Brinzolamide—glaucoma	0.000324	0.000852	CcSEcCtD
Dabrafenib—Vomiting—Acetazolamide—glaucoma	0.000323	0.000849	CcSEcCtD
Dabrafenib—Dizziness—Brimonidine—glaucoma	0.000323	0.000848	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Clonidine—glaucoma	0.00032	0.000842	CcSEcCtD
Dabrafenib—Angiopathy—Timolol—glaucoma	0.000319	0.000839	CcSEcCtD
Dabrafenib—Myalgia—Betaxolol—glaucoma	0.000319	0.000839	CcSEcCtD
Dabrafenib—Arthralgia—Betaxolol—glaucoma	0.000319	0.000839	CcSEcCtD
Dabrafenib—Diarrhoea—Dorzolamide—glaucoma	0.000319	0.000838	CcSEcCtD
Dabrafenib—Headache—Acetazolamide—glaucoma	0.000319	0.000837	CcSEcCtD
Dabrafenib—Insomnia—Clonidine—glaucoma	0.000318	0.000836	CcSEcCtD
Dabrafenib—Immune system disorder—Timolol—glaucoma	0.000318	0.000835	CcSEcCtD
Dabrafenib—Diarrhoea—Travoprost—glaucoma	0.000318	0.000834	CcSEcCtD
Dabrafenib—Mediastinal disorder—Timolol—glaucoma	0.000317	0.000833	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000317	0.000833	CcSEcCtD
Dabrafenib—Asthenia—Pilocarpine—glaucoma	0.000316	0.00083	CcSEcCtD
Dabrafenib—Arrhythmia—Timolol—glaucoma	0.000315	0.000826	CcSEcCtD
Dabrafenib—Diarrhoea—Brinzolamide—glaucoma	0.000314	0.000823	CcSEcCtD
Dabrafenib—Dry mouth—Betaxolol—glaucoma	0.000312	0.00082	CcSEcCtD
Dabrafenib—Pruritus—Pilocarpine—glaucoma	0.000312	0.000818	CcSEcCtD
Dabrafenib—Alopecia—Timolol—glaucoma	0.000311	0.000817	CcSEcCtD
Dabrafenib—Mental disorder—Timolol—glaucoma	0.000309	0.00081	CcSEcCtD
Dabrafenib—Dizziness—Dorzolamide—glaucoma	0.000308	0.00081	CcSEcCtD
Dabrafenib—Rash—Brimonidine—glaucoma	0.000308	0.000808	CcSEcCtD
Dabrafenib—Dermatitis—Brimonidine—glaucoma	0.000307	0.000807	CcSEcCtD
Dabrafenib—Dizziness—Travoprost—glaucoma	0.000307	0.000806	CcSEcCtD
Dabrafenib—Malnutrition—Timolol—glaucoma	0.000307	0.000805	CcSEcCtD
Dabrafenib—Erythema—Timolol—glaucoma	0.000307	0.000805	CcSEcCtD
Dabrafenib—Oedema—Betaxolol—glaucoma	0.000306	0.000804	CcSEcCtD
Dabrafenib—Headache—Brimonidine—glaucoma	0.000306	0.000803	CcSEcCtD
Dabrafenib—Decreased appetite—Clonidine—glaucoma	0.000306	0.000803	CcSEcCtD
Dabrafenib—Infection—Betaxolol—glaucoma	0.000304	0.000799	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Clonidine—glaucoma	0.000304	0.000798	CcSEcCtD
Dabrafenib—Fatigue—Clonidine—glaucoma	0.000303	0.000796	CcSEcCtD
Dabrafenib—Dizziness—Brinzolamide—glaucoma	0.000303	0.000796	CcSEcCtD
Dabrafenib—Nausea—Acetazolamide—glaucoma	0.000302	0.000793	CcSEcCtD
Dabrafenib—Diarrhoea—Pilocarpine—glaucoma	0.000301	0.000791	CcSEcCtD
Dabrafenib—Constipation—Clonidine—glaucoma	0.000301	0.00079	CcSEcCtD
Dabrafenib—Nervous system disorder—Betaxolol—glaucoma	0.0003	0.000789	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betaxolol—glaucoma	0.0003	0.000787	CcSEcCtD
Dabrafenib—Skin disorder—Betaxolol—glaucoma	0.000297	0.000781	CcSEcCtD
Dabrafenib—Vomiting—Dorzolamide—glaucoma	0.000296	0.000778	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betaxolol—glaucoma	0.000296	0.000777	CcSEcCtD
Dabrafenib—Rash—Dorzolamide—glaucoma	0.000294	0.000772	CcSEcCtD
Dabrafenib—Dermatitis—Dorzolamide—glaucoma	0.000294	0.000771	CcSEcCtD
Dabrafenib—Rash—Travoprost—glaucoma	0.000293	0.000769	CcSEcCtD
Dabrafenib—Dermatitis—Travoprost—glaucoma	0.000292	0.000768	CcSEcCtD
Dabrafenib—Headache—Dorzolamide—glaucoma	0.000292	0.000767	CcSEcCtD
Dabrafenib—Vomiting—Brinzolamide—glaucoma	0.000291	0.000765	CcSEcCtD
Dabrafenib—Dizziness—Pilocarpine—glaucoma	0.000291	0.000765	CcSEcCtD
Dabrafenib—Headache—Travoprost—glaucoma	0.000291	0.000764	CcSEcCtD
Dabrafenib—Nausea—Brimonidine—glaucoma	0.00029	0.000761	CcSEcCtD
Dabrafenib—Rash—Brinzolamide—glaucoma	0.000289	0.000759	CcSEcCtD
Dabrafenib—Vision blurred—Timolol—glaucoma	0.000289	0.000759	CcSEcCtD
Dabrafenib—Dermatitis—Brinzolamide—glaucoma	0.000289	0.000758	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Clonidine—glaucoma	0.000288	0.000755	CcSEcCtD
Dabrafenib—Headache—Brinzolamide—glaucoma	0.000287	0.000754	CcSEcCtD
Dabrafenib—Hypotension—Betaxolol—glaucoma	0.000286	0.000752	CcSEcCtD
Dabrafenib—Vomiting—Pilocarpine—glaucoma	0.00028	0.000735	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000279	0.000733	CcSEcCtD
Dabrafenib—Abdominal pain—Clonidine—glaucoma	0.000278	0.00073	CcSEcCtD
Dabrafenib—Body temperature increased—Clonidine—glaucoma	0.000278	0.00073	CcSEcCtD
Dabrafenib—Rash—Pilocarpine—glaucoma	0.000278	0.000729	CcSEcCtD
Dabrafenib—Dermatitis—Pilocarpine—glaucoma	0.000277	0.000729	CcSEcCtD
Dabrafenib—Insomnia—Betaxolol—glaucoma	0.000277	0.000727	CcSEcCtD
Dabrafenib—Nausea—Dorzolamide—glaucoma	0.000277	0.000727	CcSEcCtD
Dabrafenib—Headache—Pilocarpine—glaucoma	0.000276	0.000725	CcSEcCtD
Dabrafenib—Nausea—Travoprost—glaucoma	0.000276	0.000724	CcSEcCtD
Dabrafenib—Nausea—Brinzolamide—glaucoma	0.000272	0.000715	CcSEcCtD
Dabrafenib—Cough—Timolol—glaucoma	0.000268	0.000702	CcSEcCtD
Dabrafenib—Decreased appetite—Betaxolol—glaucoma	0.000266	0.000699	CcSEcCtD
Dabrafenib—Hypertension—Timolol—glaucoma	0.000265	0.000695	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000264	0.000694	CcSEcCtD
Dabrafenib—Fatigue—Betaxolol—glaucoma	0.000264	0.000693	CcSEcCtD
Dabrafenib—Constipation—Betaxolol—glaucoma	0.000262	0.000688	CcSEcCtD
Dabrafenib—Nausea—Pilocarpine—glaucoma	0.000262	0.000687	CcSEcCtD
Dabrafenib—Arthralgia—Timolol—glaucoma	0.000261	0.000685	CcSEcCtD
Dabrafenib—Myalgia—Timolol—glaucoma	0.000261	0.000685	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000259	0.000681	CcSEcCtD
Dabrafenib—Hypersensitivity—Clonidine—glaucoma	0.000259	0.000681	CcSEcCtD
Dabrafenib—Dry mouth—Timolol—glaucoma	0.000255	0.00067	CcSEcCtD
Dabrafenib—Asthenia—Clonidine—glaucoma	0.000252	0.000663	CcSEcCtD
Dabrafenib—Oedema—Timolol—glaucoma	0.00025	0.000657	CcSEcCtD
Dabrafenib—Pruritus—Clonidine—glaucoma	0.000249	0.000654	CcSEcCtD
Dabrafenib—Infection—Timolol—glaucoma	0.000249	0.000653	CcSEcCtD
Dabrafenib—Nervous system disorder—Timolol—glaucoma	0.000245	0.000644	CcSEcCtD
Dabrafenib—Skin disorder—Timolol—glaucoma	0.000243	0.000638	CcSEcCtD
Dabrafenib—Body temperature increased—Betaxolol—glaucoma	0.000242	0.000636	CcSEcCtD
Dabrafenib—Hyperhidrosis—Timolol—glaucoma	0.000242	0.000635	CcSEcCtD
Dabrafenib—Diarrhoea—Clonidine—glaucoma	0.000241	0.000632	CcSEcCtD
Dabrafenib—Hypotension—Timolol—glaucoma	0.000234	0.000614	CcSEcCtD
Dabrafenib—Dizziness—Clonidine—glaucoma	0.000233	0.000611	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Timolol—glaucoma	0.000228	0.000599	CcSEcCtD
Dabrafenib—Insomnia—Timolol—glaucoma	0.000226	0.000594	CcSEcCtD
Dabrafenib—Hypersensitivity—Betaxolol—glaucoma	0.000226	0.000593	CcSEcCtD
Dabrafenib—Vomiting—Clonidine—glaucoma	0.000224	0.000587	CcSEcCtD
Dabrafenib—Rash—Clonidine—glaucoma	0.000222	0.000582	CcSEcCtD
Dabrafenib—Dermatitis—Clonidine—glaucoma	0.000222	0.000582	CcSEcCtD
Dabrafenib—Headache—Clonidine—glaucoma	0.00022	0.000579	CcSEcCtD
Dabrafenib—Asthenia—Betaxolol—glaucoma	0.00022	0.000577	CcSEcCtD
Dabrafenib—Decreased appetite—Timolol—glaucoma	0.000217	0.000571	CcSEcCtD
Dabrafenib—Pruritus—Betaxolol—glaucoma	0.000217	0.000569	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Timolol—glaucoma	0.000216	0.000567	CcSEcCtD
Dabrafenib—Fatigue—Timolol—glaucoma	0.000216	0.000566	CcSEcCtD
Dabrafenib—Diarrhoea—Betaxolol—glaucoma	0.00021	0.00055	CcSEcCtD
Dabrafenib—Nausea—Clonidine—glaucoma	0.000209	0.000549	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Timolol—glaucoma	0.000205	0.000537	CcSEcCtD
Dabrafenib—Dizziness—Betaxolol—glaucoma	0.000203	0.000532	CcSEcCtD
Dabrafenib—Body temperature increased—Timolol—glaucoma	0.000198	0.000519	CcSEcCtD
Dabrafenib—Abdominal pain—Timolol—glaucoma	0.000198	0.000519	CcSEcCtD
Dabrafenib—Vomiting—Betaxolol—glaucoma	0.000195	0.000511	CcSEcCtD
Dabrafenib—Rash—Betaxolol—glaucoma	0.000193	0.000507	CcSEcCtD
Dabrafenib—Dermatitis—Betaxolol—glaucoma	0.000193	0.000507	CcSEcCtD
Dabrafenib—Headache—Betaxolol—glaucoma	0.000192	0.000504	CcSEcCtD
Dabrafenib—Hypersensitivity—Timolol—glaucoma	0.000184	0.000484	CcSEcCtD
Dabrafenib—Nausea—Betaxolol—glaucoma	0.000182	0.000478	CcSEcCtD
Dabrafenib—Asthenia—Timolol—glaucoma	0.00018	0.000471	CcSEcCtD
Dabrafenib—Pruritus—Timolol—glaucoma	0.000177	0.000465	CcSEcCtD
Dabrafenib—Diarrhoea—Timolol—glaucoma	0.000171	0.00045	CcSEcCtD
Dabrafenib—Dizziness—Timolol—glaucoma	0.000165	0.000434	CcSEcCtD
Dabrafenib—Vomiting—Timolol—glaucoma	0.000159	0.000418	CcSEcCtD
Dabrafenib—Rash—Timolol—glaucoma	0.000158	0.000414	CcSEcCtD
Dabrafenib—Dermatitis—Timolol—glaucoma	0.000158	0.000414	CcSEcCtD
Dabrafenib—Headache—Timolol—glaucoma	0.000157	0.000412	CcSEcCtD
Dabrafenib—Nausea—Timolol—glaucoma	0.000149	0.00039	CcSEcCtD
Dabrafenib—CYP2C8—Metabolism—NARFL—glaucoma	9.91e-05	0.000518	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CA5A—glaucoma	9.91e-05	0.000518	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—VEGFA—glaucoma	9.86e-05	0.000515	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—CDKN1B—glaucoma	9.81e-05	0.000512	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CDKN1B—glaucoma	9.76e-05	0.000509	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MMP9—glaucoma	9.65e-05	0.000504	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—glaucoma	9.63e-05	0.000503	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HDAC9—glaucoma	9.63e-05	0.000503	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC6A1—glaucoma	9.57e-05	0.0005	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TXNIP—glaucoma	9.43e-05	0.000492	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—C3—glaucoma	9.4e-05	0.000491	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—CDKN1B—glaucoma	9.37e-05	0.000489	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—glaucoma	9.33e-05	0.000487	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—CDKN1B—glaucoma	9.32e-05	0.000487	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—CDKN1B—glaucoma	9.28e-05	0.000484	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TBK1—glaucoma	9.25e-05	0.000483	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—CDKN1B—glaucoma	9.23e-05	0.000482	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—VEGFA—glaucoma	9.19e-05	0.00048	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—GSTM1—glaucoma	9.01e-05	0.00047	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—BCL2L1—glaucoma	9e-05	0.00047	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—glaucoma	8.96e-05	0.000468	CbGpPWpGaD
Dabrafenib—CYP2C8—Metapathway biotransformation—GSTM1—glaucoma	8.89e-05	0.000464	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—CDKN1B—glaucoma	8.69e-05	0.000454	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—CDKN1B—glaucoma	8.69e-05	0.000454	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—CDKN1B—glaucoma	8.69e-05	0.000454	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA5A—glaucoma	8.64e-05	0.000451	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NARFL—glaucoma	8.64e-05	0.000451	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	8.63e-05	0.000451	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—CDKN1B—glaucoma	8.61e-05	0.00045	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—CDKN1B—glaucoma	8.55e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—CDKN1B—glaucoma	8.53e-05	0.000446	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—BAD—glaucoma	8.5e-05	0.000444	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—CDKN1B—glaucoma	8.49e-05	0.000444	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CA1—glaucoma	8.42e-05	0.00044	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—C1QB—glaucoma	8.36e-05	0.000437	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—glaucoma	8.29e-05	0.000433	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	8.26e-05	0.000431	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—glaucoma	8.22e-05	0.00043	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RPTOR—glaucoma	8.19e-05	0.000428	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	8.17e-05	0.000427	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—BAD—glaucoma	8.16e-05	0.000426	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CTSA—glaucoma	8.16e-05	0.000426	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TXN—glaucoma	8.08e-05	0.000422	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—OPN4—glaucoma	8.04e-05	0.00042	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NCK2—glaucoma	7.93e-05	0.000414	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—glaucoma	7.87e-05	0.000411	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SOD1—glaucoma	7.83e-05	0.000409	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CA1—glaucoma	7.8e-05	0.000407	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CA2—glaucoma	7.7e-05	0.000402	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—CDKN1B—glaucoma	7.69e-05	0.000402	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	7.61e-05	0.000397	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTT1—glaucoma	7.59e-05	0.000396	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	7.56e-05	0.000395	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CTSA—glaucoma	7.55e-05	0.000395	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	7.53e-05	0.000393	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	7.53e-05	0.000393	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	7.5e-05	0.000392	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HEYL—glaucoma	7.48e-05	0.000391	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TXN—glaucoma	7.45e-05	0.000389	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—glaucoma	7.37e-05	0.000385	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—CAV1—glaucoma	7.3e-05	0.000381	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTGFR—glaucoma	7.24e-05	0.000378	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CA2—glaucoma	7.13e-05	0.000373	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	7.07e-05	0.000369	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—glaucoma	6.9e-05	0.00036	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—glaucoma	6.83e-05	0.000356	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	6.8e-05	0.000355	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HDAC9—glaucoma	6.75e-05	0.000352	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HDAC9—glaucoma	6.66e-05	0.000348	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP2—glaucoma	6.6e-05	0.000345	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—glaucoma	6.49e-05	0.000339	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	6.47e-05	0.000338	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—glaucoma	6.45e-05	0.000337	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTT1—glaucoma	6.26e-05	0.000327	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SMO—glaucoma	6.18e-05	0.000323	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—CYP1B1—glaucoma	6.05e-05	0.000316	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—glaucoma	6.05e-05	0.000316	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—MMP1—glaucoma	5.97e-05	0.000312	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	5.97e-05	0.000312	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CDKN1B—glaucoma	5.92e-05	0.000309	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	5.82e-05	0.000304	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—CAV1—glaucoma	5.72e-05	0.000299	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—glaucoma	5.69e-05	0.000297	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CDKN1B—glaucoma	5.68e-05	0.000297	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RPTOR—glaucoma	5.67e-05	0.000296	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—C3—glaucoma	5.59e-05	0.000292	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—glaucoma	5.57e-05	0.000291	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	5.53e-05	0.000289	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NCK2—glaucoma	5.49e-05	0.000287	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—FN1—glaucoma	5.45e-05	0.000284	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TXN—glaucoma	5.43e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—C3—glaucoma	5.36e-05	0.00028	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—BCL2L1—glaucoma	5.35e-05	0.000279	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA5A—glaucoma	5.32e-05	0.000278	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NARFL—glaucoma	5.32e-05	0.000278	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMO—glaucoma	5.28e-05	0.000276	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN2B—glaucoma	5.18e-05	0.00027	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.17e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	5.14e-05	0.000268	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.05e-05	0.000264	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TXN—glaucoma	5.03e-05	0.000262	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ABCA1—glaucoma	4.99e-05	0.000261	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CYP1B1—glaucoma	4.99e-05	0.000261	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—glaucoma	4.96e-05	0.000259	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—glaucoma	4.95e-05	0.000259	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	4.91e-05	0.000256	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—BAD—glaucoma	4.85e-05	0.000253	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CA1—glaucoma	4.84e-05	0.000253	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—GSTM1—glaucoma	4.84e-05	0.000253	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NTRK2—glaucoma	4.83e-05	0.000252	CbGpPWpGaD
Dabrafenib—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	4.77e-05	0.000249	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP2—glaucoma	4.71e-05	0.000246	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTSA—glaucoma	4.69e-05	0.000245	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HDAC9—glaucoma	4.67e-05	0.000244	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—BAD—glaucoma	4.65e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—glaucoma	4.45e-05	0.000233	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CA2—glaucoma	4.43e-05	0.000231	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTHFR—glaucoma	4.34e-05	0.000227	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	4.33e-05	0.000226	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	4.33e-05	0.000226	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NOS3—glaucoma	4.33e-05	0.000226	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA1—glaucoma	4.22e-05	0.00022	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTT1—glaucoma	4.21e-05	0.00022	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NGFR—glaucoma	4.14e-05	0.000216	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTSA—glaucoma	4.08e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EDN1—glaucoma	4.08e-05	0.000213	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	4.07e-05	0.000212	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APOE—glaucoma	4.04e-05	0.000211	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CAV1—glaucoma	4e-05	0.000209	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GSTM1—glaucoma	3.99e-05	0.000208	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NTRK1—glaucoma	3.94e-05	0.000206	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTT1—glaucoma	3.9e-05	0.000204	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CA2—glaucoma	3.86e-05	0.000201	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	3.85e-05	0.000201	CbGpPWpGaD
Dabrafenib—BRAF—Disease—BAD—glaucoma	3.77e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1A—glaucoma	3.7e-05	0.000193	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMO—glaucoma	3.65e-05	0.000191	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN2B—glaucoma	3.63e-05	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN2B—glaucoma	3.58e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—C3—glaucoma	3.56e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—glaucoma	3.54e-05	0.000185	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—glaucoma	3.53e-05	0.000184	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EDN1—glaucoma	3.48e-05	0.000182	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.39e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CDKN1B—glaucoma	3.37e-05	0.000176	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCA1—glaucoma	3.35e-05	0.000175	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP1B1—glaucoma	3.35e-05	0.000175	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK2—glaucoma	3.34e-05	0.000174	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—glaucoma	3.28e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—C3—glaucoma	3.25e-05	0.00017	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CAV1—glaucoma	3.25e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDKN1B—glaucoma	3.24e-05	0.000169	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	3.21e-05	0.000167	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NGF—glaucoma	3.2e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—glaucoma	3.18e-05	0.000166	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TXN—glaucoma	3.12e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—glaucoma	3.12e-05	0.000163	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2L1—glaucoma	3.11e-05	0.000163	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCA1—glaucoma	3.11e-05	0.000162	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP1B1—glaucoma	3.11e-05	0.000162	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—C3—glaucoma	3.04e-05	0.000159	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—glaucoma	3.03e-05	0.000158	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—glaucoma	3e-05	0.000157	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGFR—glaucoma	2.87e-05	0.00015	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.85e-05	0.000149	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—glaucoma	2.83e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BAD—glaucoma	2.82e-05	0.000147	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.82e-05	0.000147	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CAV1—glaucoma	2.8e-05	0.000146	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—glaucoma	2.8e-05	0.000146	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CAV1—glaucoma	2.77e-05	0.000145	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—glaucoma	2.77e-05	0.000145	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	2.75e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—glaucoma	2.72e-05	0.000142	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK1—glaucoma	2.72e-05	0.000142	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TXN—glaucoma	2.72e-05	0.000142	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GSTM1—glaucoma	2.68e-05	0.00014	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FN1—glaucoma	2.67e-05	0.000139	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—BAD—glaucoma	2.64e-05	0.000138	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CDKN1B—glaucoma	2.62e-05	0.000137	CbGpPWpGaD
Dabrafenib—RAF1—Disease—BAD—glaucoma	2.61e-05	0.000136	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA1—glaucoma	2.6e-05	0.000136	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTSA—glaucoma	2.52e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN2B—glaucoma	2.51e-05	0.000131	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GSTM1—glaucoma	2.48e-05	0.00013	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—glaucoma	2.46e-05	0.000128	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.42e-05	0.000126	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTT1—glaucoma	2.42e-05	0.000126	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EDN1—glaucoma	2.41e-05	0.000126	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CA2—glaucoma	2.38e-05	0.000124	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—glaucoma	2.37e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—glaucoma	2.36e-05	0.000123	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—glaucoma	2.25e-05	0.000117	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGF—glaucoma	2.21e-05	0.000116	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—glaucoma	2.21e-05	0.000115	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—glaucoma	2.19e-05	0.000115	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAV1—glaucoma	2.19e-05	0.000114	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—glaucoma	2.12e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTT1—glaucoma	2.11e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C3—glaucoma	2.1e-05	0.00011	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—glaucoma	2.09e-05	0.000109	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—glaucoma	2.04e-05	0.000107	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAV1—glaucoma	2.02e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—glaucoma	1.97e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—glaucoma	1.96e-05	0.000102	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.95e-05	0.000102	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CAV1—glaucoma	1.94e-05	0.000101	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCA1—glaucoma	1.93e-05	0.000101	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1B1—glaucoma	1.93e-05	0.000101	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—glaucoma	1.92e-05	0.0001	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—glaucoma	1.85e-05	9.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—glaucoma	1.84e-05	9.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BAD—glaucoma	1.82e-05	9.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—glaucoma	1.81e-05	9.48e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—glaucoma	1.7e-05	8.88e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ABCA1—glaucoma	1.68e-05	8.77e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1B1—glaucoma	1.68e-05	8.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TXN—glaucoma	1.67e-05	8.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—glaucoma	1.65e-05	8.63e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—glaucoma	1.54e-05	8.05e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—glaucoma	1.53e-05	7.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—glaucoma	1.53e-05	7.98e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—glaucoma	1.51e-05	7.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—glaucoma	1.47e-05	7.66e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—glaucoma	1.4e-05	7.31e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—glaucoma	1.36e-05	7.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—glaucoma	1.34e-05	7.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—glaucoma	1.3e-05	6.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—glaucoma	1.27e-05	6.64e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—glaucoma	1.27e-05	6.62e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAV1—glaucoma	1.26e-05	6.56e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—glaucoma	1.19e-05	6.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—glaucoma	1.18e-05	6.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—glaucoma	1.15e-05	6.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—glaucoma	1.1e-05	5.77e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAV1—glaucoma	1.09e-05	5.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—glaucoma	1.06e-05	5.52e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1B1—glaucoma	1.03e-05	5.4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCA1—glaucoma	1.03e-05	5.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—glaucoma	9.5e-06	4.96e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—glaucoma	8.69e-06	4.54e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—glaucoma	8.27e-06	4.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—glaucoma	8.27e-06	4.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—glaucoma	7.99e-06	4.17e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—glaucoma	7.57e-06	3.95e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—glaucoma	7.31e-06	3.82e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—glaucoma	6.8e-06	3.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAV1—glaucoma	6.74e-06	3.52e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—glaucoma	5.1e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—glaucoma	4.66e-06	2.43e-05	CbGpPWpGaD
